0.4571
price down icon1.96%   -0.0029
 
loading
전일 마감가:
$0.46
열려 있는:
$0.4577
하루 거래량:
24,390
Relative Volume:
0.10
시가총액:
$17.26M
수익:
-
순이익/손실:
$-58.52M
주가수익비율:
-0.2187
EPS:
-2.09
순현금흐름:
$-45.03M
1주 성능:
-3.16%
1개월 성능:
-8.41%
6개월 성능:
-41.50%
1년 성능:
-69.93%
1일 변동 폭
Value
$0.452
$0.47
1주일 범위
Value
$0.45
$0.4919
52주 변동 폭
Value
$0.224
$1.8199

Nextcure Inc Stock (NXTC) Company Profile

Name
명칭
Nextcure Inc
Name
전화
240-399-4900
Name
주소
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Name
직원
43
Name
트위터
@nextcureinc
Name
다음 수익 날짜
2025-03-07
Name
최신 SEC 제출 서류
Name
NXTC's Discussions on Twitter

NXTC을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NXTC
Nextcure Inc
0.46 17.26M 0 -58.52M -45.03M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
453.41 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.07 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
315.65 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
561.45 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.74 28.51B 3.81B -644.79M -669.77M -6.24

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-11-04 다운그레이드 Ladenburg Thalmann Buy → Neutral
2022-03-01 개시 Ladenburg Thalmann Buy
2021-03-05 업그레이드 Truist Hold → Buy
2021-01-15 다운그레이드 BofA Securities Neutral → Underperform
2020-07-16 업그레이드 The Benchmark Company Hold → Buy
2020-07-13 다운그레이드 ROTH Capital Buy → Neutral
2020-07-13 다운그레이드 SunTrust Buy → Hold
2020-06-01 다운그레이드 BofA/Merrill Buy → Neutral
2020-06-01 다운그레이드 The Benchmark Company Buy → Hold
2020-05-26 개시 JMP Securities Mkt Outperform
2020-03-24 개시 The Benchmark Company Buy
2020-03-02 개시 ROTH Capital Buy
2020-01-13 개시 SunTrust Buy
2019-12-05 개시 Needham Buy
2019-11-26 개시 BTIG Research Buy
2019-07-09 개시 BofA/Merrill Buy
2019-06-03 개시 Morgan Stanley Overweight
2019-06-03 개시 Piper Jaffray Overweight
모두보기

Nextcure Inc 주식(NXTC)의 최신 뉴스

pulisher
Jun 17, 2025

Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com

Jun 17, 2025
pulisher
Jun 17, 2025

Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter

Jun 17, 2025
pulisher
Jun 17, 2025

NextCure and Simcere partner to develop SIM0505 for solid tumours - Yahoo Finance

Jun 17, 2025
pulisher
Jun 16, 2025

NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure partners with Simcere Zaiming on cancer drug development - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Simcere Enters Strategic License Agreement with NextCure for Oncology Advancements - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

NextCure Lands Massive $745M Deal for Revolutionary Cancer Drug: Phase 1 Trials Starting Q3 2025 - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Billionaire Terry Smith, "the English Warren Buffett," Is Selling Meta Platforms and Microsoft and Buying This Stock That's Trouncing the Market in 2025 - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Is Lucid Stock a Millionaire-Maker? - The Globe and Mail

Jun 16, 2025
pulisher
Jun 12, 2025

JD.com Underperforms Industry in 3 Months: Should You Book Profits? - The Globe and Mail

Jun 12, 2025
pulisher
Jun 12, 2025

Whitbread (LON:WTB) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Can Shopify's Expanding Merchant Base Sustain Its Growth Momentum? - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Baidu Bets Big on AI: Is the Cloud Business Finally Paying Off? - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

SFIX Q3 Loss Narrower Than Expected, FY25 Outlook Raised, Stock Up 8% - The Globe and Mail

Jun 11, 2025
pulisher
Jun 10, 2025

COIN Outpaces Industry in 3 Months: Time to Buy the Stock? - The Globe and Mail

Jun 10, 2025
pulisher
Jun 05, 2025

Power Corporation's President and Chief Executive Officer R. Jeffrey Orr to speak at the Scotiabank Financials Summit - The Globe and Mail

Jun 05, 2025
pulisher
Jun 05, 2025

Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews

Jun 05, 2025
pulisher
Jun 05, 2025

Best Dollar Store Stock to Buy: Dollar Tree or Dollar General? - The Globe and Mail

Jun 05, 2025
pulisher
Jun 02, 2025

2 No-Brainer Growth Stocks to Buy in June - The Globe and Mail

Jun 02, 2025
pulisher
May 31, 2025

The Next Stock I'm Buying? - The Globe and Mail

May 31, 2025
pulisher
May 29, 2025

NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 - Insider Monkey

May 29, 2025
pulisher
May 29, 2025

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - The Manila Times

May 29, 2025
pulisher
May 29, 2025

NextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025 - Nasdaq

May 29, 2025
pulisher
May 29, 2025

First-in-Human Trial: NextCure's Revolutionary Cancer Drug Shows Promise Against 5 Hard-to-Treat Tumors - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews

May 29, 2025
pulisher
May 23, 2025

Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - Yahoo Finance

May 23, 2025
pulisher
May 21, 2025

Here's How I'd Invest $10,000 Today - The Globe and Mail

May 21, 2025
pulisher
May 20, 2025

Grant Williamson appointed as Canada Leader for Willis - The Globe and Mail

May 20, 2025
pulisher
May 17, 2025

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’ - The Globe and Mail

May 17, 2025
pulisher
May 14, 2025

Is Enbridge Stock Still Worth Owning After Strong Q1 Earnings? - The Globe and Mail

May 14, 2025
pulisher
May 13, 2025

Is Archer Aviation Stock (ACHR) a “Buy” Ahead of Q1 Earnings? - The Globe and Mail

May 13, 2025
pulisher
May 02, 2025

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times

May 02, 2025
pulisher
May 02, 2025

NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025
pulisher
May 02, 2025

NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks

May 02, 2025
pulisher
May 01, 2025

NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

NextCure, Inc. SEC 10-Q Report - TradingView

May 01, 2025
pulisher
May 01, 2025

NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan

May 01, 2025
pulisher
Apr 28, 2025

NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView

Apr 28, 2025

Nextcure Inc (NXTC) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.84
price up icon 0.94%
$36.26
price up icon 0.78%
$20.72
price down icon 2.91%
$99.17
price down icon 1.14%
$107.07
price up icon 0.55%
biotechnology ONC
$241.68
price down icon 0.39%
자본화:     |  볼륨(24시간):